Celastrol decreases specificity proteins (Sp) and fibroblast growth factor receptor-3 (FGFR3) in bladder cancer cells

Carcinogenesis

Volumn 33, Issue 4, 2012, Pages 886-894

  Chadalapaka, Gayathri ^a   Jutooru, Indira ^a   Safe, Stephen ^a,b  

^a TEXAS A AND M UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELASTROL; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MICRORNA; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; TRANSCRIPTION FACTOR SP4;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER CELL; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INDUCTION; GENE CONTROL; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84859572083     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs102     Document Type: Article

References (44)

1. Jemal, A. et al. (2010) Cancer statistics, 2010. CA Cancer J. Clin., 60, 277-300.
2. Kompier, L. C. et al. (2009) The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour. J. Pathol., 218, 104-112.
3. Dreicer, R. (2001) Locally advanced and metastatic bladder cancer. Curr. Treat. Options Oncol., 2, 431-436.
4. Kamat, A. M. et al. (2007) Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in IFNalpha-sensitive and IFN-alpha-resistant human bladder cancer cells. Mol. Cancer Ther., 6, 1022-1030.
5. Paneau, C. et al. (1992) [Epidemiology of bladder cancer]. Ann. Urol. (Paris), 26, 281-293.
6. Dinney, C. P. et al. (2004) Focus on bladder cancer. Cancer Cell, 6, 111-116.
7. Kassouf, W. et al. (2006) Inhibition of bladder tumor growth by 1, 1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes: a new class of peroxisome proliferator-activated receptor gamma agonists. Cancer Res., 66, 412-418.
8. Chadalapaka, G. et al. (2008) Curcumin decreases specificity protein expression in bladder cancer cells. Cancer Res., 68, 5345-5354.
9. Chadalapaka, G. et al. (2010) Drugs that target specificity proteins downregulate epidermal growth factor receptor in bladder cancer cells. Mol. Cancer Res., 8, 739-750.
10. Kannaiyan, R. et al. (2011) Celastrol inhibits proliferation and induces chemosensitization through downregulation of NF-kappaB and STAT3 regulated gene products in multiple myeloma cells. Br. J. Pharmacol., 164, 1506-1521.
11. Corson, T. W. et al. (2007) Molecular understanding and modern application of traditional medicines: triumphs and trials. Cell, 130, 769-774.
12. Dai, Y. et al. (2010) Natural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaB. PLoS One, 5, e14153.
13. McEwen, D. G. et al. (1998) Regulation of the fibroblast growth factor receptor 3 promoter and intron I enhancer by Sp1 family transcription factors. J. Biol. Chem., 273, 5349-5357.
14. Huang, Y. et al. (2008) Celastrol inhibits the growth of human glioma xenografts in nude mice through suppressing VEGFR expression. Cancer Lett., 264, 101-106.
15. Jang, S. Y. et al. (2011) Celastrol inhibits the growth of estrogen positive human breast cancer cells through modulation of estrogen receptor alpha. Cancer Lett., 300, 57-65.
16. Abbas, S. et al. (2007) Preclinical studies of celastrol and acetyl isogambogic acid in melanoma. Clin. Cancer Res., 13, 6769-6778.
17. Pang, X. et al. (2010) Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res., 70, 1951-1959.
18. Peng, B. et al. (2010) HSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way. Mol. Cancer, 9, 79.
19. Chen, G. et al. (2011) Celastrol targets mitochondrial respiratory chain complex I to induce reactive oxygen species-dependent cytotoxicity in tumor cells. BMC Cancer, 11, 170.
20. Yang, H. et al. (2006) Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine, " is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res., 66, 4758-4765.
21. Zhu, H. et al. (2010) Celastrol acts as a potent antimetastatic agent targeting beta1 integrin and inhibiting cell-extracellular matrix adhesion, in part via the p38 mitogen-activated protein kinase pathway. J. Pharmacol. Exp. Ther., 334, 489-499.
22. Kim, Y. et al. (2009) Celastrol binds to ERK and inhibits FcepsilonRI signaling to exert an anti-allergic effect. Eur. J. Pharmacol., 612, 131-142.
23. Qing, J. et al. (2009) Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J. Clin. Invest., 119, 1216-1229.
24. Abdelrahim, M. et al. (2006) Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J. Natl. Cancer Inst., 98, 855-868.
25. Jutooru, I. et al. (2010) Methyl 2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate decreases specificity protein transcription factors and inhibits pancreatic tumor growth: role of microRNA-27a. Mol. Pharmacol., 78, 226-236.
26. Pathi, S. S. et al. (2011) GT-094, a NO-NSAID, inhibits colon cancer cell growth by activation of a reactive oxygen species-microRNA-27a: ZBTB10-specificity protein pathway. Mol. Cancer Res., 9, 195-202.
27. Kim, K. et al. (2012) Identification of oncogenic microRNA-17-92/ZBTB4/specificity protein axis in breast cancer. Oncogene., 31, 1034-1044.
28. Mertens-Talcott, S. U. et al. (2007) The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res., 67, 11001-11011.
29. Jutooru, I. et al. (2010) Arsenic trioxide downregulates specificity protein (Sp) transcription factors and inhibits bladder cancer cell and tumor growth. Exp. Cell Res., 316, 2174-2188.
30. Kannaiyan, R. et al. (2011) Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer. Cancer Lett., 303, 9-20.
31. Hieronymus, H. et al. (2006) Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell, 10, 321-330.
32. Zhang, T. et al. (2008) A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol. Cancer Ther., 7, 162-170.
33. Zhang, T. et al. (2009) Characterization of celastrol to inhibit hsp90 and cdc37 interaction. J. Biol. Chem., 284, 35381-35389.
34. Laederich, M. B. et al. (2011) Fibroblast growth factor receptor 3 (FGFR3) is a strong heat shock protein 90 (Hsp90) client: implications for therapeutic manipulation. J. Biol. Chem., 286, 19597-19604.
35. Lee, Y. et al. (2004) MicroRNA genes are transcribed by RNA polymerase II. EMBO J., 23, 4051-4060.
36. Woods, K. et al. (2007) Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors. J. Biol. Chem., 282, 2130-2134.
37. Trachootham, D. et al. (2008) Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood, 112, 1912-1922.
38. Nagase, M. et al. (2003) Apoptosis induction in HL-60 cells and inhibition of topoisomerase II by triterpene celastrol. Biosci. Biotechnol. Biochem., 67, 1883-1887.
39. Gomez-Roman, J. J. et al. (2005) Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. Clin. Cancer Res., 11, 459-465.
40. Tomlinson, D. C. et al. (2007) FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J. Pathol., 213, 91-98.
41. van Rhijn, B. W. et al. (2001) The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res., 61, 1265-1268.
42. van Rhijn, B. W. et al. (2002) Frequent FGFR3 mutations in urothelial papilloma. J. Pathol., 198, 245-251.
43. Chintharlapalli, S. et al. (2007) Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res., 67, 2816-2823.
44. Tillotson, L. G. (1999) RIN ZF, a novel zinc finger gene, encodes proteins that bind to the CACC element of the gastrin promoter. J. Biol. Chem., 274, 8123-8128.